ReviewMicroorganisms2023
SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo.
Review in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- SARS-CoV-2 antibody-dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors.JCI insight · 2026Article
- B Cell Receptor's function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism.PLoS pathogens · 2026Article
- FcγR-ACE2 cooperative antibody-dependent enhancement in human and veterinary coronaviruses: mechanistic insights, comparative immunology, and implications for nano-engineered immunomodulatory platforms.Frontiers in immunology · 2026Review
- Antibodies Against SARS-CoV-2 Nucleocapsid Protein Possess Autoimmune Properties.Antibodies (Basel, Switzerland) · 2025Article
- Cross-reactivity IgG, viral load, severity and vaccination outcome as an approach for understanding humoral immune response against SARS-CoV-2.BMC infectious diseases · 2025Article
- Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.NPJ vaccines · 2025Article
- Protective Potential and Functional Role of Antibodies Against SARS-CoV-2 Nucleocapsid Protein.Antibodies (Basel, Switzerland) · 2025Article
- Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.International journal of molecular sciences · 2025Review
- Immunogenic Potential of Selected Peptides from SARS-CoV-2 Proteins and Their Ability to Block S1/ACE-2 Binding.Viruses · 2025Article
- Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025Review
- Article
- Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.Pathogens (Basel, Switzerland) · 2024Review
- Exploring the Contrasts and Similarities of Dengue and SARS-CoV-2 Infections During the COVID-19 Era.International journal of molecular sciences · 2024Review
- Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.Nature reviews. Immunology · 2024Review
- Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.International journal of molecular sciences · 2024Article
- MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity.Pathogens (Basel, Switzerland) · 2024Article
- Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.Microorganisms · 2024Review
- Article
- Enhancement of SARS-CoV-2 Infection via Crosslinking of Adjacent Spike Proteins by N-Terminal Domain-Targeting Antibodies.Viruses · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antibody-dependent enhancement (ADE) is a phenomenon in which antibodies produced in the body after infection or vaccination may enhance subsequent viral infections in vitro and in vivo. Although rare, symptoms of viral diseases are also enhanced by ADE following infection or vaccination in vivo. This is thought to be due to the production of antibodies with low neutralizing activity that bind to the virus and facilitate viral entry, or antigen-antibody complexes that cause airway inflammation, or a predominance of T-helper 2 cells among the immune system cells which leads to excessive eosinophilic tissue infiltration. Notably, ADE of infection and ADE of disease are different phenomena that overlap. In this article, we will describe the three types of ADE: (1) Fc receptor (FcR)-dependent ADE of infection in macrophages, (2) FcR-independent ADE of infection in other cells, and (3) FcR-dependent ADE of cytokine production in macrophages. We will describe their relationship to vaccination and natural infection, and discuss the possible involvement of ADE phenomena in COVID-19 pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.